Cargando…

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma

Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced toxicity profile, we introduced Treo/Flu as conditioning before aut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frietsch, Jochen J., Miethke, Jenny, Linke, Paul, Crodel, Carl C., Schnetzke, Ulf, Scholl, Sebastian, Hochhaus, Andreas, Hilgendorf, Inken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262709/ https://www.ncbi.nlm.nih.gov/pubmed/35538141 http://dx.doi.org/10.1038/s41409-022-01701-x

Ejemplares similares

Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms
por: O‘Hagan Henderson, Samantha, et al.
Publicado: (2021)

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation
por: Frietsch, Jochen J, et al.
Publicado: (2019)

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient
por: Frietsch, Jochen J., et al.
Publicado: (2019)

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy
por: Mühleck, Regina, et al.
Publicado: (2021)

Isolation of Hafnia paralvei co-harbouring bla(NDM-1) and bla(VIM-1) in a woman who underwent allogeneic hematopoietic stem cell transplantation
por: Appel, Tobias Manuel, et al.
Publicado: (2023)

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT
por: Bug, Gesine, et al.
Publicado: (2023)

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity
por: Frietsch, Jochen J., et al.
Publicado: (2020)

Psychosocial distress in young adults surviving hematological malignancies: a pilot study
por: Wittwer, Andreas, et al.
Publicado: (2022)

A 19-year-old patient with atypical chronic myeloid leukemia
por: Ernst, Philipp, et al.
Publicado: (2020)

The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm
por: O’Hagan Henderson, Samantha, et al.
Publicado: (2021)

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient
por: Voigt, Margarete, et al.
Publicado: (2021)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis
por: Braitsch, Krischan, et al.
Publicado: (2022)

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation
por: Pulewka, Kristin, et al.
Publicado: (2020)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
por: Finke, Jürgen, et al.
Publicado: (2022)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Treatment of relapsed extranodal natural killer/T-cell lymphoma with bortezomib plus fludarabine
por: Chen, Chen, et al.
Publicado: (2017)

PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023)

DNA alkylation and interstrand cross-linking by treosulfan
por: Hartley, J A, et al.
Publicado: (1999)

Treosulfan-based conditioning for inborn errors of immunity
por: Slatter, Mary A., et al.
Publicado: (2021)

Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT
por: Saraceni, Francesco, et al.
Publicado: (2023)

Fludarabine-containing chemotherapy for patients with previously untreated low-grade non-Hodgkin's lymphoma
por: Ahn, Jae-Sook, et al.
Publicado: (2011)

Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation
por: van der Stoep, M. Y. E. C., et al.
Publicado: (2019)

SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2020)

Treosulfan induces distinctive gonadal toxicity compared with busulfan
por: Levi, Mattan, et al.
Publicado: (2018)

In Vitro Study of the Enzymatic and Nonenzymatic Conjugation of Treosulfan with Glutathione
por: Romański, Michał, et al.
Publicado: (2019)

Publisher Correction: SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders
por: Kaiser, Alexander, et al.
Publicado: (2021)

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
por: Atagunduz, Isik Kaygusuz, et al.
Publicado: (2020)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
por: Scordo, Michael, et al.
Publicado: (2023)

In Vivo Red Blood Cells/Plasma Partition Coefficient of Treosulfan and Its Active Monoepoxide in Rats
por: Romański, Michał, et al.
Publicado: (2018)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gi4d27mf4ndm427pe9i37u0ujp